KCNQ2 antisense RNA 1 (KCNQ2-AS1)

KCNQ2 antisense RNA 1 (KCNQ2-AS1) is a long non-coding RNA molecule produced from the KCNQ2 locus on the genome, transcribed in the antisense direction relative to the KCNQ2 gene itself[5]. As with other antisense RNAs and long non-coding RNAs, KCNQ2-AS1 is presumed to have roles in the regulation of gene expression, potentially through effects on chromatin or transcriptional interference with the sense (protein-coding) KCNQ2 transcript. There is presently very limited published or validated functional information specific to KCNQ2-AS1; however, by analogy with other characterized antisense RNAs, it may influence either neuronal development or disease states by modulating KCNQ2 expression[3]. No drugs are known to target KCNQ2-AS1, and there are no validated clinical applications as a biomarker or therapeutic target at this time. KCNQ2-AS1 should not be confused with the KCNQ2 gene, which encodes a voltage-gated potassium channel subunit crucial for neuronal excitability and is an established therapeutic and disease gene in epilepsy and developmental disorders[1][2]. KCNQ2-AS1 is not considered a conventional therapeutic target, enzyme, receptor, transporter, or transcription factor. It is most accurately described as a long non-coding antisense RNA molecule[3][5]. There are currently no specific disease roles, interacting drugs, or mechanisms of action described in the literature for KCNQ2-AS1 itself, differentiating it sharply from the KCNQ2 protein product.

Other names

KCNQ2-AS1KCNQ2 antisense RNA 1

Not applicable; antisense RNAs regulate gene expression at the RNA level rather than acting as direct drug targets